Considering a change to your treatment regimen? Columnist Mary Shaniqua shares tips to help patients and providers make an ...

Most people with SCD seem to meet or exceed current level of physical activity recommendations for the general population, a ...

To mark four years of sharing his experiences through writing, columnist Dunstan Nicol-Wilson reflects on the journey with gratitude.

Columnist Oluwatosin Adesoye shares her thoughts about the role of World Sickle Cell Day in promoting sickle cell awareness.

Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela holds a PhD in Molecular Biology from the University of Salzburg, where her ...

The BEACON trial (NCT05456880), which began dosing last year, is evaluating the safety and efficacy of BEAM-101 in people with severe SCD, ages 18-35, who have had at least four VOCs in the two years ...

The treatment’s developer, Beam Therapeutics, shared data from the first 17 patients dosed in the trial in a presentation, “Base editing for sickle cell disease: ongoing results from the BEACON study ...